Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.57
AZN's Cash to Debt is ranked higher than
61% of the 810 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.19 vs. AZN: 0.57 )
AZN' s 10-Year Cash to Debt Range
Min: 0.2   Max: No Debt
Current: 0.57

Equity to Asset 0.38
AZN's Equity to Asset is ranked higher than
52% of the 756 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. AZN: 0.38 )
AZN' s 10-Year Equity to Asset Range
Min: 0.3   Max: 0.59
Current: 0.38

0.3
0.59
Interest Coverage 7.50
AZN's Interest Coverage is ranked higher than
54% of the 490 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 76.05 vs. AZN: 7.50 )
AZN' s 10-Year Interest Coverage Range
Min: 6.85   Max: 100.5
Current: 7.5

6.85
100.5
F-Score: 4
Z-Score: 2.48
M-Score: -2.96
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 11.82
AZN's Operating margin (%) is ranked higher than
79% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.96 vs. AZN: 11.82 )
AZN' s 10-Year Operating margin (%) Range
Min: 1.47   Max: 38.09
Current: 11.82

1.47
38.09
Net-margin (%) 7.82
AZN's Net-margin (%) is ranked higher than
78% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.39 vs. AZN: 7.82 )
AZN' s 10-Year Net-margin (%) Range
Min: 6.86   Max: 29.72
Current: 7.82

6.86
29.72
ROE (%) 8.79
AZN's ROE (%) is ranked higher than
78% of the 795 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.37 vs. AZN: 8.79 )
AZN' s 10-Year ROE (%) Range
Min: 10.72   Max: 45.6
Current: 8.79

10.72
45.6
ROA (%) 3.54
AZN's ROA (%) is ranked higher than
72% of the 814 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.13 vs. AZN: 3.54 )
AZN' s 10-Year ROA (%) Range
Min: 4.6   Max: 21.04
Current: 3.54

4.6
21.04
ROC (Joel Greenblatt) (%) 51.06
AZN's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 810 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.57 vs. AZN: 51.06 )
AZN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 3.32   Max: 192.75
Current: 51.06

3.32
192.75
Revenue Growth (%) -5.10
AZN's Revenue Growth (%) is ranked higher than
56% of the 665 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. AZN: -5.10 )
AZN' s 10-Year Revenue Growth (%) Range
Min: -54.5   Max: 87.7
Current: -5.1

-54.5
87.7
EBITDA Growth (%) -14.50
AZN's EBITDA Growth (%) is ranked higher than
57% of the 629 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.80 vs. AZN: -14.50 )
AZN' s 10-Year EBITDA Growth (%) Range
Min: -40.8   Max: 112.8
Current: -14.5

-40.8
112.8
EPS Growth (%) -29.50
AZN's EPS Growth (%) is ranked higher than
57% of the 626 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.00 vs. AZN: -29.50 )
AZN' s 10-Year EPS Growth (%) Range
Min: -29.5   Max: 71.5
Current: -29.5

-29.5
71.5
» AZN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

AZN Guru Trades in Q3 2013

Steven Cohen 532,113 sh (+4346.87%)
Pioneer Investments 590,122 sh (+23.7%)
Charles Brandes 2,381,040 sh (+7.92%)
David Dreman 179,261 sh (+4.4%)
Murray Stahl 12,020 sh (+0.17%)
NWQ Managers 85,850 sh (unchged)
Manning & Napier Advisors, Inc 508,945 sh (-0.53%)
HOTCHKIS & WILEY 4,912,449 sh (-0.65%)
Jim Simons 2,913,800 sh (-14.94%)
John Hussman 68,000 sh (-81.87%)
» More
Q4 2013

AZN Guru Trades in Q4 2013

Francis Chou 13,000 sh (New)
Stanley Druckenmiller 360,500 sh (New)
Pioneer Investments 651,839 sh (+10.46%)
Charles Brandes 2,503,848 sh (+5.16%)
Steven Cohen 533,262 sh (+0.22%)
Murray Stahl 12,020 sh (unchged)
NWQ Managers 85,450 sh (-0.47%)
Manning & Napier Advisors, Inc 490,878 sh (-3.55%)
Jim Simons 2,715,400 sh (-6.81%)
HOTCHKIS & WILEY 3,689,214 sh (-24.9%)
David Dreman 106,975 sh (-40.32%)
John Hussman 28,000 sh (-58.82%)
» More
Q1 2014

AZN Guru Trades in Q1 2014

Joel Greenblatt 95,518 sh (New)
John Hussman 228,000 sh (+714.29%)
David Dreman 135,439 sh (+26.61%)
Murray Stahl 13,106 sh (+9.03%)
Stanley Druckenmiller 360,500 sh (unchged)
Francis Chou 13,000 sh (unchged)
NWQ Managers 85,450 sh (unchged)
HOTCHKIS & WILEY Sold Out
Manning & Napier Advisors, Inc 459,569 sh (-6.38%)
Pioneer Investments 459,298 sh (-29.54%)
Steven Cohen 367,034 sh (-31.17%)
Charles Brandes 1,333,894 sh (-46.73%)
Jim Simons 1,429,000 sh (-47.37%)
» More
Q2 2014

AZN Guru Trades in Q2 2014

Louis Moore Bacon 40,000 sh (New)
Mario Gabelli 40,400 sh (New)
Jeremy Grantham 28,000 sh (New)
George Soros 150,000 sh (New)
Paul Tudor Jones 27,100 sh (New)
Jim Simons 1,794,800 sh (+25.6%)
Daniel Loeb 1,000,000 sh (unchged)
Steven Cohen 225,000 sh (unchged)
Francis Chou 13,000 sh (unchged)
Steven Cohen 370,800 sh (unchged)
Joel Greenblatt Sold Out
Murray Stahl 13,000 sh (-0.81%)
John Hussman 223,500 sh (-1.97%)
David Dreman 117,832 sh (-13%)
NWQ Managers 64,475 sh (-24.55%)
Manning & Napier Advisors, Inc 309,030 sh (-32.76%)
Stanley Druckenmiller 208,900 sh (-42.05%)
Pioneer Investments 225,804 sh (-50.84%)
Charles Brandes 386,058 sh (-71.06%)
» More
» Details

Insider Trades

Latest Guru Trades with AZN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Charles Brandes 2014-06-30 Reduce -71.06%0.78%$62.45 - $81.09 $ 69-4%386058
Joel Greenblatt 2014-06-30 Sold Out 0.09%$62.45 - $81.09 $ 69-4%0
George Soros 2014-06-30 New Buy0.08%$62.45 - $81.09 $ 69-4%150000
Mario Gabelli 2014-06-30 New Buy0.02%$62.45 - $81.09 $ 69-4%40400
NWQ Managers 2014-06-30 Reduce -24.55%0.01%$62.45 - $81.09 $ 69-4%64475
John Hussman 2014-03-31 Add 714.29%0.96%$58.51 - $68.15 $ 697%228000
HOTCHKIS & WILEY 2014-03-31 Sold Out 0.93%$58.51 - $68.38 $ 697%0
Charles Brandes 2014-03-31 Reduce -46.73%0.84%$58.51 - $68.15 $ 697%1333894
David Dreman 2014-03-31 Add 26.61%0.14%$58.51 - $68.38 $ 697%135439
Joel Greenblatt 2014-03-31 New Buy0.09%$58.51 - $68.38 $ 697%95518
David Dreman 2013-12-31 Reduce -40.32%0.34%$49.72 - $59.5 $ 6927%106975
HOTCHKIS & WILEY 2013-12-31 Reduce -24.9%0.3%$49.72 - $59.5 $ 6927%3689214
John Hussman 2013-12-31 Reduce -58.82%0.11%$49.72 - $59.5 $ 6927%28000
John Hussman 2013-09-30 Reduce -81.87%0.66%$47.88 - $52.08 $ 6937%68000
Charles Brandes 2013-09-30 Add 7.92%0.12%$47.88 - $52.08 $ 6937%2381040
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 43.70
AZN's P/E(ttm) is ranked higher than
75% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 41.40 vs. AZN: 43.70 )
AZN' s 10-Year P/E(ttm) Range
Min: 6.07   Max: 47.24
Current: 43.7

6.07
47.24
P/B 4.14
AZN's P/B is ranked higher than
67% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.26 vs. AZN: 4.14 )
AZN' s 10-Year P/B Range
Min: 2.31   Max: 7.02
Current: 4.14

2.31
7.02
P/S 3.35
AZN's P/S is ranked higher than
73% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.61 vs. AZN: 3.35 )
AZN' s 10-Year P/S Range
Min: 1.6   Max: 4.13
Current: 3.35

1.6
4.13
PFCF 23.53
AZN's PFCF is ranked higher than
92% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. AZN: 23.53 )
AZN' s 10-Year PFCF Range
Min: 6.67   Max: 38.17
Current: 23.53

6.67
38.17
EV-to-EBIT 29.83
AZN's EV-to-EBIT is ranked higher than
77% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.26 vs. AZN: 29.83 )
AZN' s 10-Year EV-to-EBIT Range
Min: 4.5   Max: 142.6
Current: 29.83

4.5
142.6
Shiller P/E 13.33
AZN's Shiller P/E is ranked higher than
97% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 97.53 vs. AZN: 13.33 )
AZN' s 10-Year Shiller P/E Range
Min: 8.05   Max: 27.94
Current: 13.33

8.05
27.94
Current Ratio 0.99
AZN's Current Ratio is ranked lower than
51% of the 809 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.28 vs. AZN: 0.99 )
AZN' s 10-Year Current Ratio Range
Min: 0.64   Max: 2.03
Current: 0.99

0.64
2.03
Quick Ratio 0.85
AZN's Quick Ratio is ranked higher than
52% of the 809 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.75 vs. AZN: 0.85 )
AZN' s 10-Year Quick Ratio Range
Min: 0.54   Max: 2.03
Current: 0.85

0.54
2.03

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 4.06
AZN's Dividend Yield is ranked higher than
95% of the 493 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.34 vs. AZN: 4.06 )
AZN' s 10-Year Dividend Yield Range
Min: 1.68   Max: 6.75
Current: 4.06

1.68
6.75
Dividend Payout 1.74
AZN's Dividend Payout is ranked higher than
82% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.21 vs. AZN: 1.74 )
AZN' s 10-Year Dividend Payout Range
Min: 0.24   Max: 4.87
Current: 1.74

0.24
4.87
Dividend growth (3y) 3.20
AZN's Dividend growth (3y) is ranked higher than
80% of the 360 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.70 vs. AZN: 3.20 )
AZN' s 10-Year Dividend growth (3y) Range
Min: -6.3   Max: 30.1
Current: 3.2

-6.3
30.1
Yield on cost (5-Year) 5.80
AZN's Yield on cost (5-Year) is ranked higher than
95% of the 500 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.42 vs. AZN: 5.80 )
AZN' s 10-Year Yield on cost (5-Year) Range
Min: 2.38   Max: 9.56
Current: 5.8

2.38
9.56
Share Buyback Rate 4.60
AZN's Share Buyback Rate is ranked higher than
92% of the 593 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.10 vs. AZN: 4.60 )
AZN' s 10-Year Share Buyback Rate Range
Min: 43.7   Max: -144.8
Current: 4.6

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.13
AZN's Price/DCF (Projected) is ranked higher than
94% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.71 vs. AZN: 1.13 )
AZN' s 10-Year Price/DCF (Projected) Range
Min: 0.5   Max: 4.43
Current: 1.13

0.5
4.43
Price/Median PS Value 1.43
AZN's Price/Median PS Value is ranked higher than
66% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.24 vs. AZN: 1.43 )
AZN' s 10-Year Price/Median PS Value Range
Min: 0.7   Max: 2.48
Current: 1.43

0.7
2.48
Earnings Yield (Greenblatt) 3.40
AZN's Earnings Yield (Greenblatt) is ranked higher than
68% of the 669 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. AZN: 3.40 )
AZN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.7   Max: 22.2
Current: 3.4

0.7
22.2
Forward Rate of Return (Yacktman) -4.12
AZN's Forward Rate of Return (Yacktman) is ranked higher than
62% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.19 vs. AZN: -4.12 )
AZN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -6   Max: 30.2
Current: -4.12

-6
30.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:AZN.Sweden, AZNDF.USA, AZN.UK, ZEGA.Germany, ZEG.Germany, AZNCF.USA, AZN N.Mexico
AstraZeneca PLC is engaged in the global, prescription-based biopharmaceutical business. Its pharmaceuticals business consists of the discovery and development of new products, which are then manufactured, marketed and sold. It focuses on six therapy areas of healthcare such as Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory & Inflammation. The Company has operations in the United Kingdom, Continental Europe, The Americas, Asia, Africa, and Australia.
» More Articles for NYSE:AZN

Headlines

Articles On GuruFocus.com
Steven Cohen Has a Track Record of Impressive Returns Jul 31 2014 
I Believe AstraZeneca Is Fairly Valued Jul 16 2014 
A Look at AstraZeneca’s New Drug on Diabetes May 22 2014 
Gulf Resources (GURE) Impressive Performance, Amgen (AMGN) and AstraZeneca (AZN) Positive Data From May 11 2014 
Can Pfizer Make Up Its Loss? May 09 2014 
Abbott Capturing Incremental Market Share Mar 18 2014 
Abbvie's Humira Continues to be a Powerful Catalyst for Growth Mar 18 2014 
10 British Stocks to Consider Feb 20 2014 
Bristol-Myers: Don’t Let This One Get Away Jan 15 2014 
AstraZeneca: Time to Make a Bet? Steven Cohen Seems to Think It Is Jan 15 2014 


More From Other Websites
Markets open for trading: AbbVie/Shire deal scrapped Oct 21 2014
Will GlaxoSmithKline (GSK) Earnings Suffer on China Probe? Oct 20 2014
The shares tipped to fall if Labour wins next year’s general election Oct 20 2014
BUZZ-European healthcare: safety check Oct 20 2014
Pfizer/AZ chase may be off as pharma deals falter Oct 20 2014
Ironwood/Actavis Move Linzess into Phase II Study for OIC Oct 17 2014
Why AQR Capital exits its position in Tableau Software Inc. Oct 17 2014
Roche, Merck extend immunotherapy fight to breast cancer Oct 17 2014
Why AQR Capital opens a new position in Equinix Oct 16 2014
Tax inversion clampdown leaves M&A engineers seeking new oil for the deal machine Oct 16 2014
Questor special: FTSE 100 defensive shares for a market panic Oct 16 2014
Why AQR Capital starts a new position in Navient Oct 16 2014
Why AQR Capital opens new a position in AstraZeneca Oct 16 2014
How Much Lower Can Shire PLC Go? Oct 16 2014
Why Smith & Nephew plc’s Latest Failure Should Worry AstraZeneca plc And GlaxoSmithKline plc Oct 16 2014
AstraZeneca strengthens partnership with the University of Cambridge Oct 16 2014
Shire - AbbVie: Turning the screw on tax inversions Oct 15 2014
Overview: AQR Capital Management’s 2Q14 positions Oct 15 2014
FTSE 100 teetering on edge of correction; Shire sinks in London Oct 15 2014
Shire Falls, AbbVie Questioned On Buyout Backtrack Oct 15 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK